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central line-associated infection. C. parapsilosis has higher minimal inhibitory concentration
to echinocandin than Candida albicans, and the effects of echinocandin on C. parapsilosis
are ambiguous. Therefore, in this study, we aimed to investigate the susceptibility and the cor-
relation between incidence and drug consumption.
Methods: This retrospective study was conducted in a tertiary teaching hospital in northern
Taiwan between 2008 and 2012. The Candida species distribution, the correlation between
the use of antifungal agents and the incidence of C. parapsilosis bloodstream infection, demo-
graphic information, clinical characteristics, mortality rate, and in vitro susceptibility of C.
parapsilosis were analyzed.
Results: A total of 77 episodes from 77 patients were included for analysis. The overall 90-day
mortality rate was 41.6%. The incidence of C. parapsilosis bloodstream infection showed a
moderate positive correlation with the increased defined daily dose of echinocandin. The risk
factors associated with mortality included malignancy or a metastatic tumor. Multivariate
logistical regression analysis showed that patients with malignancy had higher odds ratios innfectious Diseases, Department of Internal Medicine, Mackay Memorial Hospital, Number 92, Section
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Candida parapsilosis bloodstream infection 553terms of mortality. The rate of C. parapsilosis resistance to fluconazole was 3%, whereas the
susceptibility rate was 95.5%.
Conclusion: Underlying comorbidity and malignancy were factors leading to death in patients
with C. parapsilosis bloodstream infection. Catheter removal did not influence the mortality
rate. The survival rate of patients receiving echinocandinwas lower than the group receiving flu-
conazole. Fluconazole remains thedrugof choice to treatC.parapsilosisbloodstream infections.
Copyright ª 2014, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. All rights
reserved.Introduction
Candida parapsilosis was the third most isolated pathogen
among Candida species in both North America and
Taiwan.1,2 According to an epidemiological study in North
America, C. parapsilosis accounted for 15.9% of all isolated
organisms from 3648 patients.2 It is higher in some hospital
services, such as neonatal intensive care units, where it
accounts for 30.6% of all isolated Candida species from
neonatal intensive care unit patients in North America.2 In
the epidemiological study in Taiwan, C. parapsilosis re-
mains the third most frequent Candida species. Candida
albicans accounts for 50% of candidemia, whereas C. par-
apsilosis accounts for about 10% of the candidemia.1 In
addition, C. parapsilosis accounts for 47.8% of neonatal
candidemia, based on a study that enrolled 46 neonates in
Taiwan from 1994 to 1997.3 According to a review article
published in 2008, the mortality rate of C. parapsilosis
bloodstream infections was 28.5%.4
C. parapsilosis is a normal human commensal, which is
often isolated from hand skin. It presents an oval, round, or
cylindrical shape while appearing creamy, white, shiny, and
smooth or wrinkled on Sabouraud dextrose agar.5 Intact
human skin limits the pathogenicity of C. parapsilosis. It is
notorious for its affinity for catheter or prosthetic materials,
capacity for forming biofilm and ability to grow in hyperali-
mentation solution.6 A study in Spain revealed that the risk
factors of C. parapsilosis infection include vascular cathe-
terization, previous antibiotics history, previous immunosup-
pressive therapy, malignancy, transplant receipt,
neutropenia, and previous colonization.7 Several articles
described the outbreak of C. parapsilosis infections either in
neonate or adult intensive care units. Molecular typing
methods revealed a link between hand carriage of C. para-
psilosis from health care workers and the pathogen of the
patients. Hand hygiene thus plays an important role in the
prevention of the outbreak of C. parapsilosis infections.4,6,8,9
With regard to the increasing incidence of C. parapsilosis, its
correlation with a high mortality rate and association with
hand hygiene, it is important to conduct further research
regarding C. parapsilosis.
Materials and methods
Study population
A retrospective study was conducted at a 2200-bed tertiary
teaching hospital with burn care and solid organtransplantation facilities, but without bone marrow trans-
plantation facilities in northern Taiwan. We enrolled the
patients whose blood culture yielded C. parapsilosis during
hospitalization from June 2008 to June 2012. The medical
records of patients were reviewed, and data such as de-
mographic characteristics, medical history, invasive pro-
cedures, medications, laboratory data, and outcomes were
collected for analysis. We also have reviewed medical
literature for comparison of C. parapsilosis in vitro anti-
microbial susceptibility.
Inclusion criteria
C. parapsilosis bloodstream infection was defined as the
presence of a positive blood culture of C. parapsilosis with
concomitant signs and symptoms of infection.10 C. para-
psilosis bloodstream infection was considered to be health
care-associated infections if it occurred more than 48 hours
after admission.11 If multiple episodes of C. parapsilosis
bloodstream infection occurred in the same patient during
the study period, the patient was included as a study
participant using only the first episode of candidemia.12 In
the study period, a total of 77 patients whose blood culture
yielding C. parapsilosis met the inclusion criteria.
Definition of terms
Death was considered to be attributable to C. parapsilosis
bloodstream infection if any of the following was noted
during the same hospital stay: death within 7 days after a
positive blood culture for C. parapsilosis; absence of any
cause of fatality; death in the presence of clinical evidence
of persistent candidiasis (e.g., persistent fever, hypoten-
sion, or positive cultures for C. parapsilosis at clinically
involved sites, such as peritoneal fluid, renal abscess, or
endophthalmitis); autopsy evidence of disseminated
candidiasis; or cause of death as C. parapsilosis blood-
stream infection on the death certificate.13,14
The patient was considered a survivor of C. parapsilosis
bloodstream infection if either of the following was noted
regarding the same hospital stay: survival at discharge or
improvement of C. parapsilosis bloodstream infection
associated symptoms without recurrence within 30 days.
The incidence of candidemia was defined as the number
of cases of candidemia per 1000 inpatient-days.15 Defined
daily dose is a statistical measure of drug consumption,
defined by the World Health Organization. It is used to
standardize the comparison of drug usage between
554 C.-C. Lin et al.different drugs or between different health care
environments.
Species identification and antifungal susceptibility
testing
Blood samples were tested daily for microbial growth using
the BACTEC FX system (Becton Dickinson Diagnostic In-
strument Systems, Sparks, MD, USA). Organisms were
initially identified by germ tube analysis and colony
morphology on Sabouraud dextrose agar. If necessary, they
were determined using a VITEK 2 yeast identification card
(bioMe´rieux SA, Marcy-l’Etoile, France). In this study, sus-
ceptibility testing of isolates was performed using eight
antifungal agents (voriconazole, posaconazole, itracona-
zole, fluconazole, caspofungin, micafungin, anidulafungin,
and amphotericin B) with a Sensititre YeastOne Colori-
metric Antifungal Panel used according to the manufac-
turer’s instructions. Susceptibilities of C. parapsilosis to
the above antifungal agents were read according to the
interpretative breakpoints approved by the European
Committee on Antimicrobial Susceptibility Testing and the
Clinical Laboratory Standards Institute for susceptibility
testing of Candida species.16
Statistical analysis
Univariate analyses were used to identify the risk factors
associated with candidemia-related death. A Pearson’s Chi
square test or Fisher’s exact two-tailed test was used toTable 1 The incidence and Candida species distribution of can
Annual inpatient days
2008 2009
565,839 595,28
Species identification Number of isolates (%
Candida albicans 66 (55.9) 58 (47.
Incidence 0.12 0.10
Candida glabrata 19 (16.1) 12 (9.8
Incidence 0.03 0.02
Candida parapsilosis 13 (11.0) 14 (11.
Incidence 0.02 0.02
Candida tropicalis 14 (11.8) 23 (18.
Incidence 0.02 0.04
Candida krusei 0 3 (2.5)
Incidence 0 0.01
Candida dubliniensis 1 (0.8) 0
Candida famata 0 0
Candida guilliermondii 1 (0.8) 0
Candida haemulonii 0 0
Candida lusitaniae 1 (0.8) 0
Candida pelliculosa 0 0
Candida rugosa 0 1 (0.8)
Candida utilis 0 1 (0.8)
Candida lipolytica 0 0
Candida norvegensis 0 0
Candida species 3 (2.5) 10 (8.2
Total 118 122examine nominal data, and the unpaired Student t test was
used for continuous data. A p value of <0.05 was consid-
ered statistically significant. The independent predictors of
candidemia-associated mortality were identified by step-
wise logistic regression of multivariate analysis for the
significant risk factors on the univariate analyses. SPSS for
Windows version 21.0 (SPSS Inc., Chicago, IL, USA) software
was used for statistical analysis. Linear regression analysis
was used to analyze the trend in annual consumption of
antifungal agents and the incidence of patients with can-
didemia over time. Pearson’s product moment correlation
coefficient was used to determine the relationship between
annual consumption of antifungal agents and the trend in
candidemia incidence. A p value of <0.05 was considered
statistically significant.
Results
In Table 1, the incidence levels of candidemia in our hos-
pital from 2008 to 2012 are listed. The overall incidence of
candidemia showed a significant increase (p < 0.05). The
incidence of individual Candida species did not significantly
increase by year. However, the incidence of C. parapsilosis
showed a mild decrease although it did not reach statistical
significance.
A total of 77 episodes were identified retrospectively in
77 patients with C. parapsilosis candidemia. The univariate
analysis of risk factors of C. parapsilosis candidemia-
associated mortality in 77 patients is summarized in
Table 2. About 58% (45/77) were male, and the mean age
was 50.5  30.9 years. About 25% (19/77) of the patientsdidemia from 2008 to 2012
2010 2011 2012 p
8 589,075 605,233 578,422
)
5) 71 (51.1) 77 (47.5) 79 (45.1) 0.434
0.12 0.13 0.14
) 20 (14.4) 30 (18.5) 28 (16.0) 0.363
0.03 0.05 0.05
4) 10 (7.2) 22 (13.6) 18 (10.3) 0.509
0.01 0.04 0.03
9) 27 (19.4) 19 (11.7) 28 (16.0) 0.226
0.05 0.03 0.05
1 (0.7) 0 3 (1.7) 0.136
0.00 0 0.01
1 (0.7) 0 1 (0.5) 0.775
0 2 (1.2) 0 0.144
1 (0.7) 5 (3.1) 3 (1.7) 0.261
0 (0) 2 (1.2) 0 0.144
1 (0.7) 1 (0.6) 0 0.683
1 (0.7) 1 (0.6) 0 0.794
0 0 1 (0.5) 0.706
0 0 0 0.335
1(0.7) 0 0 0.529
0 0 1 (0.5) p > 0.999
) 5 (3.6) 3 (1.9) 13 (7.4) 0.031
139 162 175 0.002
Table 2 Univariate analysis of risk factors of Candida
parapsilosis candidemia-associated mortality
Variable (%) Survival
(n Z 45)
Death
(n Z 32)
p
Sex, male 25 (55.6) 20 (62.5) 0.542
Age < 8 y 16 (35.6) 3 (9.4) 0.009
Onset of candidemia in ICU 16 (35.6) 3 (9.4) 0.009
Underlying disease
Recent intra-abdominal
surgery
13 (28.9) 9 (28.1) 0.942
Recent chemotherapy 8 (17.8) 12 (37.5) 0.052
Chronic steroid therapy 3 (6.7) 3 (9.4) 0.688
Diabetes mellitus 8 (17.8) 12 (37.5) 0.913
End-stage renal disease 3 (6.7) 1 (3.1) 0.637
COPD 1 (2.2) 4 (12.5) 0.154
Chronic liver disease 7 (15.6) 7 (21.9) 0.479
Any maligency 17 (37.8) 26 (81.3) <0.001
Leukemia 1 (2.2) 2 (6.3) 0.567
Gastrointestinal malignancy 8 (17.8) 10 (31.3) 0.169
Metastatic solid tumor 5 (11.1) 11 (34.4) 0.013
Neutropenia 6 (13.3) 5 (15.6) >0.999
Catheter
Hickmann catheter 4 (8.9) 1 (3.1) 0.395
Port-A 12 (26.7) 14 (50) 0.118
CVC 28 (62.2) 16 (50) 0.285
Femoral CVC 12 (26.7) 6 (18.8) 0.419
Catheter all 44 (91.1) 31 (93.8) >0.999
Remove CVC 26 (33.8) 26 (33.8) 0.410
TPN 4 (8.9) 2 (6.3) >0.999
PPN 13 (28.9) 15 (46.9) 0.106
TPN þ PPN 17 (37.8) 17 (53.1) 0.181
Fluconazole 26 (59.1) 18 (40.9) 0.894
Echinocandin 6 (46.2) 7 (53.8) 0.324
Amphotericin B 9 (81.8) 2 (18.2) 0.089
Voriconazole 3 (50) 3 (50) 0.894
COPDZ chronic obstructive pulmonary disease; CVCZ central
venous catheter; ICU Z intensive care unit; PPN Z partial
parenteral nutrition; TPN Z total parenteral nutrition.
Table 3 Multivariate logistic regression analysis of risk
factors associated with mortality in episodes of candidemia
Odds ratio 95% CI p
Age < 18 y 0.39 0.09e1.79 0.227
Onset of candidemia in ICU 0.77 0.13e4.39 0.767
Any malignancy 4.08 1.03e16.14 0.045
Metastatic solid tumor 1.72 0.46e6.45 0.419
CI Z confidence interval; ICU Z intensive care unit.
Candida parapsilosis bloodstream infection 555were younger than 18 years. The overall mortality attrib-
utable to C. parapsilosis candidemia was about 42% (32/
77). Risk factors of mortality in the univariate analysis
included patients with malignancy (p < 0.001) or a meta-
static tumor (p Z 0.013). By contrast, patients younger
than 18 years and or whose candidemia was discovered in
the intensive care unit showed a better survival rate
(pZ 0.009). A multivariate logistic regression analysis, the
results of which are listed in Table 3, showed that patients
with malignancy had a higher odds ratio in terms of mor-
tality (p Z 0.045).
A total of 75 patients (75/77) had a central line-
associated route when they acquired a C. parapsilosis
bloodstream infection. Five patients had a Hickman cath-
eter, 26 patients had a port-A, and 44 patients had a central
venous catheter (CVC), which included 18 patients with
femoral CVC. However, the kind of catheter used did not
contribute to mortality (Table 2).
The minimal inhibitory concentration (MIC) of 67 C.
parapsilosis in our study, which were identified byYeastOne commercial disk, is summarized in Table 4. The
MIC50/MIC90 of fluconazole was 1/2 (range 0.25e8),
amphotericin B was 1/1 (range 0.25e1), anidulafungin was
1/2 (range 0.12e2), micafungin was 1/2 (range 0.25e4),
caspofungin was 0.5/1 (range 0.25e1), voriconazole was
0.008/0.15 (range 0.008e0.15), posaconazole was 0.03/
0.06 (range 0.015e0.12), and itraconazole was 0.06/0.12
(range 0.015e0.25). The C. parapsilosis susceptibility rate
to fluconazole was 95.5%, whereas the resistance rate was
3%. We included papers mentioning the fluconazole resis-
tance rate of C. parapsilosis and those giving full coverage
of antifungal agents. The result is also listed in Table 4.
The correlation between the annual consumption of
antifungal agents and the incidence of C. parapsilosis
bloodstream infection was calculated using Pearson’s
product moment correlation coefficient (results shown in
Table 5). The incidence of C. parapsilosis bloodstream
infection increased, whereas the annual consumption of
echinocandin increased during the study period. C. para-
psilosis bloodstream infection showed a moderate positive
correlation with the use of echinocandin, but this correla-
tion was not statistically significant (Pearson
correlation Z 0.614, p Z 0.271).
Discussion
The incidence of all candidemia cases in the hospital was
0.25 per 1000 patient-days, which shows a significant in-
crease from 2008 to 2012; the incidence also increased
significantly from 0.10 to 0.15 per 1000 patient-days from
1999 to 2006 in Taiwan.1 In the meantime, the incidence of
candidemia ranged from 0.45 to 0.46 per 1000 admission-
days in America and ranged from 0.2 to 0.38 in Europe.17
Ruan and Hsueh17 mentioned that the incidence of candi-
demia from 1980 to the end of 1990s increased. This was
followed by a relatively stable period in Taiwan, but it
continued to increase significantly in the 2000s.17
The distribution of Candida species shows regional dif-
ferences.18 In this study, C. albicans (49.0%) was the most
frequently isolated species, followed by C. tropicalis
(15.5%), C. glabrata (15.2%), and C. parapsilosis (10.8%).
The rate of isolated C. parapsilosis was 13.3%, which is
close to the average rate in the Asia-Pacific area (13.7%),
but lower than the global average (17.2%) from 2008 to
2009.19 Three studies during 1994 to 2000 from northern
Taiwan reported the rate of isolated C. parapsilosis to be
around 11.2e17.5%.20e22 Pfaller et al23,24 reported global
data showing that the rate of isolated C. parapsilosis from
1992 to 2001 was 13.1% and 15%. The distribution in the
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Table 5 Correlation between the use of the antifungal
agents and the incidence of Candida parapsilosis blood-
stream infection
C. parapsilosis
Fluconazole total Pearson correlation 0.643
Sig. (2-tailed) 0.241
Fluconazole IV Pearson correlation 0.486
Sig. (2-tailed) 0.407
Fluconazole oral Pearson correlation 0.586
Sig. (2-tailed) 0.299
Echinocandin total Pearson correlation 0.614
Sig. (2-tailed) 0.271
Caspofungin Pearson correlation 0.086
Sig. (2-tailed) 0.891
Micafungin Pearson correlation 0.800
Sig. (2-tailed) 0.104
Anidulafungin Pearson correlation 0.390
Sig. (2-tailed) 0.516
Voriconazole Pearson correlation 0.162
Sig. (2-tailed) 0.795
Amphotericin B Pearson correlation 0.787
Sig. (2-tailed) 0.114
556 C.-C. Lin et al.hospital was similar to that reported in the Asia-Pacific
area, and although C. tropicalis was higher than C. glab-
rata, the rates of the following three non-albicans Candida
spp. were close.
C. parapsilosis is a common skin colonizer. It is most
often isolated from neonates and children and related to
intravenous instrumentation. The risk factors of patients
who developed C. parapsilosis bloodstream infections
include prolonged use of catheter or indwelling device,
hyperalimentation solution infusion, gastrointestinal sur-
gery, presence of immune compromising conditions such as
AIDS, recent chemotherapy or use of immune compressive
agents, previous colonization, previous antibiotics treat-
ment, or previous antifungal agent treatment.4 Chen et al25
found that patients with C. parapsilosis bloodstream in-
fections had higher blood albumin levels, lower Sequential
Organ Failure Assessment scores, and frequently those who
had total parental nutrition infusions would have lower
mortality rates. In our study, the mortality rate was 41.6%,
which is higher than that (28.5%) reported in a review
article in 2008 or in 2012 (30%).2,4 The risk factors of
mortality included those patients with any malignancy or
presence of a metastatic tumor. By contrast, patients
younger than 18 years had lower mortality rates. Further-
more, in multivariate logistical regression analysis, patients
with malignancy had a higher odds ratio in terms of mor-
tality. However, the drug selection, total parental nutrition
infusion, type of catheter, or the site of CVC did not in-
crease the risk of mortality. Andes et al26 report that
echinocandin, CVC removal, and Acute Physiology and
Chronic Health Evaluation II score were independently
associated with mortality in non-albicans Candida species
infections, but only disease severity predicted the survival
of patients with C. parapsilosis and C. tropicalis infections.
In our study, the results supported similar con-
clusionsdthat underlying comorbidity and malignancy
Candida parapsilosis bloodstream infection 557were the factors leading to death. C. parapsilosis blood-
stream infection was merely a confounding accident.
The Infectious Diseases Society of America guidelines for
the management of candidiasis in 2009 suggested flucona-
zole for nonneutropenic patients with C. parapsilosis in-
fections, and fluconazole or liposomal amphotericin B for
neutropenic patients. The susceptibility of C. parapsilosis
to echinocandin was susceptible to resistance, even though
in vitro resistance was uncommon.27 The in vitro activity of
antifungal agents against C. parapsilosis from this study
and other articles are summarized in Table 4.28e37 About 3%
of isolated C. parapsilosis in our study were resistant to
fluconazole. This rate is similar to the global data. How-
ever, a high resistance rate of fluconazole was noted in
China. The authors of two articles mentioned the cross
resistance between fluconazole and voriconazole, and
suggested using non-azole antifungal agents and consis-
tently monitoring susceptibility.32,33 Echinocandin is a new
class of antifungal agents. The echinocandin MICs of C.
parapsilosis are higher than those of other Candida species.
In our study, only one isolated C. parapsilosis was inter-
mediate to micafungin. The other isolates were susceptible
to in vitro echinocandin. However, the survival rate of
patients receiving echinocandin was lower than that of
patients receiving fluconazole (46.2% vs. 59.1%). Ampho-
tericin B was traditionally the most commonly prescribed
antifungal agent. The reported resistance rate of C. para-
psilosis to amphotericin B was 2e3%.4 In our study, no iso-
lated C. parapsilosis was resistant to amphotericin B
in vitro. The clinical response was better compared with
other agents. However, because of its nephrotoxicity and
the high cost of liposomal amphotericin B, their annual
consumption was on the decrease. In our study, fluconazole
remains the drug of choice to treat C. parapsilosis blood-
stream infections.
Caspofungin was introduced to our hospital in 2003,
followed by micafungin in 2009, and then anidulafungin in
2011. It is hypothesized that the increasing use of anti-
fungal agents, such as fluconazole, increases the selection
pressure on non-albicans Candida species. However, con-
flicting results have been reported, and thus the hypothesis
remains controversial.17 Given the high MIC of C. para-
psilosis, some articles mention the selection pressure
associated with the increasing use of echinocandin.2 How-
ever, Lai et al15 reported a significant negative correlation
between the incidence of C. parapsilosis infection and the
use of echinocandin and voriconazole. In our study, C.
parapsilosis bloodstream infection showed a moderate
positive correlation with the use of echinocandin, but this
correlation was not statistically significant. Many factors
influence the incidence of C. parapsilosis bloodstream
infection. The advocacy of hand hygiene campaign started
in our hospital in 2009. Furthermore, the CVC care bundle
was launched in the intensive care unit in our hospital in
2010. The reinforcement of infection control would reduce
the infection rate of C. parapsilosis. Although the use of
antifungal agents is not the only factor influencing the
incidence of C. parapsilosis infection, our study does not
support the hypothesis that increasing use of echinocandin
increases the incidence of C. parapsilosis infection.
Underlying comorbidity and malignancy were factors
leading to death in patients with C. parapsilosisbloodstream infection. Catheter removal did not influence
the mortality rate. The survival rate of patients receiving
echinocandin was lower than that in the group receiving
fluconazole. Fluconazole remains the drug of choice to
treat C. parapsilosis bloodstream infections.References
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